MALVERN, PA — Endo, Inc. (OTCQX: NDOI) revealed new insights from a post hoc data analysis of its Phase 3 clinical trial of ...

More than a decade after earning FDA approval for Xiaflex as a nonsurgical treatment option for Dupuytren’s contracture, Endo is debuting its first-ever branded TV commercial in the indication.

(OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or CCH) in patients with Peyronie's disease (PD ...

Just over a week ago, the Pennsylvania-based drugmaker unveiled a branded campaign for Xiaflex, its treatment for the progressive hand condition that affects around 17 million Americans. The 60-second ...

Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum ...

Steve, a patient with Dupuytren’s contracture (curled fingers), gets to hold hands with his wife again in Endo’s first-ever commercial touting how its decade-old Xiaflex can treat the condition.

The campaign, featuring a real Dupuytren's contracture patient, encourages patients to consult a hand specialist and ask about XIAFLEX® (collagenase clostridium histolyticum), the only FDA ...

"By spotlighting authentic experiences like Steve's, we are emboldening patients to connect with a hand specialist and ask for nonsurgical XIAFLEX ®, positioning them as knowledgeable decision ...

Campaign builds on the momentum of Endo's disease awareness efforts. Commercial features a real patient—who was an untreated patient in a prior Endo video series—and his wife, sharing their personal ...